Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.43−0.00 (-0.95%)
Close on Nov 13, 2026Market cap $80.59MP/E –Yield –
Neumora Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Neumora Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$180.52M. For fiscal 2025 it was -$206.44M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$206.44M | – |
| FY2024 | Dec 31, 2024 | -$182.94M | – |
| FY2023 | Dec 31, 2023 | -$163.28M | – |
| FY2022 | Dec 31, 2022 | -$114.90M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$39.53M | – |
| Q1 FY2026 | Mar 31, 2026 | -$46.40M | – |
| Q4 FY2025 | Dec 31, 2025 | -$47.96M | – |
| Q3 FY2025 | Sep 30, 2025 | -$46.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$52.40M | – |
| Q1 FY2025 | Mar 31, 2025 | -$59.45M | – |
| Q4 FY2024 | Dec 31, 2024 | -$50.34M | – |
| Q3 FY2024 | Sep 30, 2024 | -$33.48M | – |
| Q2 FY2024 | Jun 30, 2024 | -$56.16M | – |
| Q1 FY2024 | Mar 31, 2024 | -$42.96M | – |
| Q4 FY2023 | Dec 31, 2023 | -$51.44M | – |
| Q3 FY2023 | Sep 30, 2023 | -$47.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.02M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.04M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.37M | – |
See a number that looks wrong?